Innovative Targeting Forge Therapeutics specializes in targeting metalloproteins through a novel approach that focuses on the metal in enzyme active sites, offering unique opportunities to develop targeted therapies for infectious diseases and cancer.

Recent Mergers The company's recent merger with Blacksmith Medicines enhances its immuno-oncology portfolio, creating potential cross-selling and collaborative opportunities with biotech firms focusing on cancer therapies.

Strategic Collaborations Forge's partnerships with Roche and Basilea Pharmaceutica, especially in antibiotic development, open avenues for co-marketing, licensing, and expanding their reach in the infectious disease treatment market.

Funding Strength With $15 million in funding and multiple government awards including CARB-X, Forge has a solid financial base to support innovative research, making it a reliable partner for joint ventures and strategic investments.

Growth Potential Operating with a lean team of 11-50 employees and a focus on cutting-edge bio-inorganic chemistry, Forge presents opportunities for technology licensing, R&D collaborations, and tailored procurement of advanced biotech solutions.